Autoanticuerpos dirigidoscontra productos de glicación avanzada en pacientes con diabetes mellitus tipo 1

• Margarita González R ^[1] ; Christine Paquién M ; Sylvia Asenjo M ; Andrea Gleisner E ; Lilian Kirsten L ; Marcelo Bustamante C
  1. [1] Universidad de Concepción

     Universidad de Concepción

     Comuna de Concepción, Chile

     
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 129, Nº. 2, 2001, págs. 141-148
• Idioma: español
• Títulos paralelos:
  • Antibodies against advanced glycation end products in patients with type 1 diabetes mellitus
• Enlaces
  • Texto completo
• Resumen

  • Background: Advanced glycation end products are associated with chronic complications of diabetes mellitus. This glycation process renders many proteins immunogenic. Aim: To detect the presence of antibodies against albumin, collagen and low density lipoprotein glycation products in boys and teenagers with diabetes mellitus. Patients and methods: Thirty one patients with diabetes mellitus type I, aged 11±3.8 years and with a mean duration of disease of 3.7±2.7 years and 31 healthy controls aged 12.4±5.3 years were studied. Antibodies against glycation end products were detected by ELISA and results were expressed as a ratio of the optical density of the glycated protein/optical density of the native protein. Results: Diabetic patients and healthy controls did not have antibodies against albumin glycation end products. Diabetics had higher levels of antibodies than controls for collagen glycation end products (2.6±0.4 and 1.8±0.2 respectively, p< 0.01) and low density lipoprotein glycation end products (3.07±0.92 and 2.2±0.72 respectively, p< 0.05). Conclusions: The biological role of these antibodies is not clear. They could be a depuration mechanism for glycation end products or contribute to chronic complications of diabetes mellitus (Rev Méd Chile 2001; 129: 141-48).